|Articles|December 19, 2017

Flu Vaccine: The Jar Is Three-Quarters Full, Not Half Empty

William Schaffner, MD, explains the strengths and weaknesses of the flu vaccine.

William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, explains the strengths and weaknesses of the flu vaccine.

Interview Transcript (modified slightly for readability):

“Flu vaccine is pretty darn good vaccine; it’s not a perfect vaccine. It’s not like the measles vaccines that will prevent measles completely. We all know that we have to get the vaccine each year because the virus mutates and we have to reformulate the vaccine. And we also know, although it protects many people completely, it may, indeed, result in some people getting influenza despite the vaccine, but it will be a milder infection. So, let’s think about the jar [as] three-quarters full, rather than half empty. Put the accent on the positive salable. We should use this vaccine, which is the best we have available today, to prevent as many illnesses as possible. Who wants to go to the hospital as a patient? Going as a doctor is one thing, but going as a patient? No. Let’s prevent that happening from flu.”


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.